Edap Tms SA
NASDAQ:EDAP

Watchlist Manager
Edap Tms SA Logo
Edap Tms SA
NASDAQ:EDAP
Watchlist
Price: 3.22 USD -2.13% Market Closed
Market Cap: $120.4m

P/E

-3.5
Current
26%
Cheaper
vs 3-y average of -4.7

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-3.5
=
Market Cap
$123.3m
/
Net Income
€-29.2m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
-3.5
=
Market Cap
$123.3m
/
Net Income
€-29.2m

Valuation Scenarios

Edap Tms SA is trading above its industry average

If P/E returns to its Industry Average (23.5), the stock would be worth $-21.46 (766% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-766%
Maximum Upside
No Upside Scenarios
Average Downside
653%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple -3.5 $3.22
0%
Industry Average 23.5 $-21.46
-766%
Country Average 15.5 $-14.15
-539%

Forward P/E
Today’s price vs future net income

Not enough data available to calculate forward P/E

Market Distribution

Lower than 100% of companies in France
Percentile
0th
Based on 1 397 companies
0th percentile
-3.5
Low
0.2 — 11
Typical Range
11 — 26.8
High
26.8 —
Distribution Statistics
France
Min 0.2
30th Percentile 11
Median 15.5
70th Percentile 26.8
Max 3 102.9

Edap Tms SA
Glance View

Market Cap
120.4m USD
Industry
Health Care

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 227 full-time employees. The firm operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The firm invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The firm is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The firm is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.

EDAP Intrinsic Value
4.25 USD
Undervaluation 24%
Intrinsic Value
Price $3.22
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett